No Data
No Data
Marker Therapeutics (NASDAQ:MRKR) Shareholders Are up 20% This Past Week, but Still in the Red Over the Last Five Years
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Marker Therapeutics' Promising Cancer Therapy Progress
Marker Therapeutics (MRKR.US): The 2024 Q1 financial report achieved revenue of $1.244 million, previous value of $1.244 million; earnings per share was -0.27 US dollars, previous value of -0.57 US dollars.
Marker Therapeutics (MRKR.US): The 2024 Q1 financial report achieved revenue of $1.244 million, previous value of $1.244 million; earnings per share was -0.27 US dollars, previous value of -0.57 US dollars.
Marker Therapeutics Q1 EPS $(0.27) Up From $(0.57) YoY, Sales $1.24M Up From $1.23M YoY
Marker Therapeutics Believes Existing Cash and Cash Equivalents Will Fund Oper Expenses Into 4Q 2025 >MRKR
No Data